Cargando…

Synergistic effect of eribulin and CDK inhibition for the treatment of triple negative breast cancer

Activation of CDK2 in triple negative breast cancer (TNBC) can contribute to non-canonical phosphorylation of a TGFβ signaling component, Smad3, promoting cell proliferation and migration. Inhibition of CDK2 was shown to decrease breast cancer oncogenesis. Eribulin chemotherapy was used effectively...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rao, Shreyas S., Stoehr, Jenna, Dokic, Danijela, Wan, Lei, Decker, Joseph T., Konopka, Kristine, Thomas, Alexandra L., Wu, Jia, Kaklamani, Virginia G., Shea, Lonnie D., Jeruss, Jacqueline S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5663565/ https://www.ncbi.nlm.nih.gov/pubmed/29137393 http://dx.doi.org/10.18632/oncotarget.20202

Ejemplares similares

Implications of TGFβ Signaling and CDK Inhibition for the Treatment of Breast Cancer
por: Decker, Joseph T., et al.
Publicado: (2021)

Engineering the pre-metastatic niche
por: Aguado, Brian A., et al.
Publicado: (2017)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Metabolic Syndrome and Triple-Negative Breast Cancer: A New Paradigm
por: Davis, Andrew A., et al.
Publicado: (2012)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Precision health for breast cancer metastasis: biomaterial scaffolds as an engineered metastatic niche to define, study, and monitor metastatic progression
por: Bushnell, Grace G., et al.
Publicado: (2019)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

PI3K inhibition enhances the anti-tumor effect of eribulin in triple negative breast cancer
por: Rajput, Sandeep, et al.
Publicado: (2019)

Eribulin in Triple Negative Metastatic Breast Cancer: Critic Interpretation of Current Evidence and Projection for Future Scenarios
por: Pizzuti, Laura, et al.
Publicado: (2019)

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer
por: Lee, Jin Sun, et al.
Publicado: (2019)

Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells
por: Pederson, Petra J., et al.
Publicado: (2021)

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer
por: Wen, Wei, et al.
Publicado: (2019)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Second-line Eribulin in Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective Study: The TETRIS Trial
por: Krasniqi, Eriseld, et al.
Publicado: (2021)

The Microtubule Destabilizer Eribulin Synergizes with STING Agonists to Promote Antitumor Efficacy in Triple-Negative Breast Cancer Models
por: Takahashi-Ruiz, Leila, et al.
Publicado: (2022)

4026 Dissecting the role of microenvironment heterogeneity on metastatic tumor cell phenotype at an engineered metastatic niche
por: Orbach, Sophia, et al.
Publicado: (2020)

Dynamic, Large-Scale Profiling of Transcription Factor Activity from Live Cells in 3D Culture
por: Weiss, Michael S., et al.
Publicado: (2010)

Dynamic Transcription Factor Networks in Epithelial-Mesenchymal Transition in Breast Cancer Models
por: Siletz, Anaar, et al.
Publicado: (2013)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Third Line Eribulin for Triple-negative Metastatic Breast Ductal Carcinoma Resulting in Extended Progression-free Survival of 57 Months
por: Manthri, Sukesh, et al.
Publicado: (2020)

Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer
por: Liu, Jieqiong, et al.
Publicado: (2022)

Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer
por: Ono, Hisako, et al.
Publicado: (2021)

Eribulin Mesylate Improves Cisplatin-Induced Cytotoxicity of Triple-Negative Breast Cancer by Extracellular Signal-Regulated Kinase 1/2 Activation
por: Ko, Hyemi, et al.
Publicado: (2022)

In vivo capture and label-free detection of early metastatic cells
por: Azarin, Samira M., et al.
Publicado: (2015)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

A synthetic metastatic niche reveals antitumor neutrophils drive breast cancer metastatic dormancy in the lungs
por: Wang, Jing, et al.
Publicado: (2023)

Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
por: Hu, Ye, et al.
Publicado: (2021)

Combination of two anti-tubulin agents, eribulin and paclitaxel, enhances anti-tumor effects on triple-negative breast cancer through mesenchymal-epithelial transition
por: Oba, Takaaki, et al.
Publicado: (2018)

Clinical benefit of treatment with eribulin mesylate for metastatic triple‐negative breast cancer: Long‐term outcomes of patients treated in the US community oncology setting
por: Mougalian, Sarah S., et al.
Publicado: (2018)

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer
por: Bagheri, Meisam, et al.
Publicado: (2023)

MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
por: Horiuchi, Dai, et al.
Publicado: (2012)

Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer
por: Ge, Jennifer Y., et al.
Publicado: (2020)

CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1
por: Li, Xiao, et al.
Publicado: (2022)

CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
por: Saleh, Lubaid, et al.
Publicado: (2021)

Proteomic characterisation of triple negative breast cancer cells following CDK4/6 inhibition
por: Beykou, Melina, et al.
Publicado: (2022)

Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial
por: Pascual, Tomás, et al.
Publicado: (2021)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_31quuta0t0m9km7d3ra5hm8ank